Dr. Martin Jernigan has joined RG+A in 2019 as President and Chief Operating Officer. In this role Martin will lead RG+A’s research, consulting and sales activities while working directly with some key clients.
Dr. Jernigan brings over 20 years of strategic pharmaceutical leadership experience in U.S. and Global commercial roles to RG+A. Most recently, he spent 12 years at Novo Nordisk where he oversaw the U.S. pre‐launch and launch of Victoza® (liraglutide) and went on to serve as Vice President, first for its GLP‐1 franchise growing it to a $2B franchise and later for its $3B insulin business. Earlier in his career, he worked in commercial, business development, strategy and marketing roles of increasing responsibility at Johnson & Johnson, Aventis, Hoechst Marion Roussel and Marion Merrell Dow.
Dr. Jernigan received his Pharmacy degree from Auburn University and a Master of Science and Ph.D. in Health Care Administration with a concentration in Pharmaceutical Marketing from the University of Mississippi. He currently teaches Pharmaceutical Marketing at Rutgers MBA global business management program.